Semaglutide
Treatment for Chronic kidney disease due to diabetes mellitus type 2
Typical Dosage: Semaglutide 0.5-2mg weekly (SC)
Effectiveness
85%
Safety Score
60%
Clinical Trials
10
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Semaglutide 0.5-2mg weekly (SC)
Time to Effect
6-12 months for sustained renal/CV benefits
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
45(Treat 45 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$11,500
Monitoring:$1,200
Side Effect Mgmt:$200
Total Annual:$12,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$140,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$18,428.57
Comparison vs ACE inhibitor/ARB alone
Cost Difference
+$11,500/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Semaglutide Outcomes
for Chronic kidney disease due to diabetes mellitus type 2
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Nausea
+30%
Vomiting
+15%
Diarrhea
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov